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Purpose: This study introduces an advanced method to 
evaluate and extent the adjustment of the prescribed dose to 
maintain the same clinical results, when changing the dose 
calculation algorithm type (a), i.e density correction method 
to more recently type (b) algorithm, i.e AAA.  
Material and methods: 10 cases with lung cancer were 
studied. For each case, 3 treatment plans were generated. 
Plan 1 was generated using type (a) algorithm, and Plan 2 
using type (b) algorithm. In plan 3 the dose was calculated 
with type (b) algorithm using monitor units from plan 1 as 
input. A global analysis based on 2D and 3D gamma (γ) was 
made to evaluate the under / overestimation of calculated 
dose. Clinical evaluation was carried out using Tumour 
Control Probability (TCP) and Normal Tissue Complication 
Probabilities (NTCP) based on Uniform Equivalent Dose 
model. Assuming a constant TCP, the ratio “R= TCP/NTCP” 
and Uncomplicated Tumor Control Probability (UTCP) were 
calculated to measure the clinical benefit – toxicity. 
Wilcoxon test was used to evaluate the significance of the 
differences and the correlation coefficient (r) was calculated 
using Spearman’s rank test. 
Results: The dose calculated with algorithm type (b) was 
significantly overestimated to organs at risks while the 
delivered dose in MU was underestimated, p < 0.001. 
Therefore, γ maps confirmed the dosimetric results. 
Moreover, there were a significant difference for NTCP for 
lung and heart. The ratio “R” from plan 1 and plan 2 were 
significantly different, indicating that to maintain the same 
effect benefit and toxicity the prescribed dose should be 
readjusted. 
Conclusion: We assessed the prescribed dose using the 
radiobiological models. The ratio of benefit was significantly 
changed when moving from type (a) algorithm to type (b) 
algorithm. This indicate that the prescribed dose should be 
readjusted when type (b) algorithm will be integrated in 
radiation oncology. A discussion between oncologist and 
physicist is quite necessary in order to readjust the 
prescribed dose. 
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Purpose: Hypoxia represents one of the most important 
challenges of current radiotherapy that can potentially affect 
the treatment planning and outcome. For the optimization of 
proton therapy and its application in treating hypoxic tumors 
such as dose and LET painting it is important to study the 
DNA damage response of normal cells under hypoxic and 
radio resistant conditions. The present study is aimed at 
understanding the variations in DNA double strand breaks 
induction and repair along prisitine and Spread-Out-Bragg-
Peak Proton beams under hypoxic. 
Materials and methods: DNA DSB damage and repair response 
was studied in AG01522 cells irradiated at various positions 
along the 62 MeV therapeutic protons Bragg peak at the 
CATANA beam line of the Institute of Nuclear Physics (INFN) 
Catania, Italy. Hypoxia was mimicked by using Cobalt 
chloride (CoCl2) and Dimethyl Sulphoxide (DMSO) was used as 
a Reactive Oxygen Species (ROS) scavenger. Hypoxia 
induction was confirmed by immunofluorescent staining of 
Hypoxia inducible factor-1 alpha (HIF-1α) and DNA DSB 
induction was quantified using p53 Binding protein-1 (53BP1) 
foci.  
Results: The presence of DMSO and CoCl2 reduced the 53BP1 
foci by 40% as compared to foci induction under normoxic 
conditions (30 minutes) in the cells irradiated at the entrance 
position of pristine beam. Cells irradiated at the Bragg peak 
revealed a significant induction of residual DSB damage even 
in presence of DMSO and CoCl2 at 24 hrs. Cells irradiated at 
distal end positions of the SOBP also revealed a significant 
induction of the 53BP1 foci irrespective of the oxygenation 
conditions of the medium. 
Conclusions: Our results indicate the variations in the 
induction and repair of DNA DSBs in presence of ROS 
scavenger and Hypoxia along the Bragg peak. These findings 
can be of potential application in the tumor treatment 
planning of hypoxic tumors especially near the critical organs 
and combining DNA repair inhibitors approach. 
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Purpose: Hypoxic tumors still pose a challenge for modern 
radiotherapy. Hadrontherapy has gained momentum world 
wide as an effective modality for tumor therapy including 
success in inducing cell death in cancer cells under hypoxia 
as reported by several investigators. Significant advances in 
laser technologies have led to the prospect of using laser-
accelerated ions, emitted in ultrashort bursts, as a future, 
cost-saving alternative to conventional accelerators. An 
understanding of the radiobiological effects at the ultrahigh 
dose rate delivered by these short ions pulses on human cells 
under hypoxic conditions is important for the development 
and further advancement of this technology towards clinical 
applications.  
Materials and methods: Laser accelerated 15-18 MeV protons 
generated using the Nd:glass VULCAN laser system at the 
Rutherford Appleton Laboratory, Oxford, UK, were delivered,  
by a compact magnetic transport system, to cell samples at 
dose rates exceeding 109 Gy/s. Dosimetry was validated using 
EBT2 gafchromic films and CR-39 tracks detector. Normal 
human skin fibroblasts (AG01522 cells) monolayers grown in 
custom made stainless steel, on 3 μm thin Mylar dishes were 
pre-gassed with hypoxic gas mixture (95% nitrogen and 5% 
Carbon-di-oxide) for 4 hours and irradiated inside portable 
beam-line hypoxia chambers. Hypoxia induction was 
confirmed using HIF-1 alpha immuostaining. DNA damage and 
repair kinetics was studied using 53BP1 foci formation assay 
up to 24 hours after irradiation under both normoxic and 
hypoxic conditions. 
Results: Our preliminary data suggests the effectiveness of 
Laser accelerated protons in DNA damage induction under 
both normoxic and hypoxic conditions. We observed a small 
reduction in average foci induction at initial time points in 
hypoxic cells, which was not seen after 2 hrs. 
